Myriad Genetics, Inc. Release: National Comprehensive Cancer Network Updates Guidelines For Hereditary Colon Cancer Testing

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SALT LAKE CITY, March 4, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today is pleased to note that the National Comprehensive Cancer Network (NCCN) has revised its medical guidelines to expand Lynch syndrome screening. Lynch syndrome is the most common cause of hereditary colon cancer in adults.

Help employers find you! Check out all the jobs and post your resume.

Back to news